Literature DB >> 14985049

SK&F 83822 distinguishes adenylyl cyclase from phospholipase C-coupled dopamine D1-like receptors: behavioural topography.

Gerard J O'Sullivan1, Bryan L Roth, Anthony Kinsella, John L Waddington.   

Abstract

Effects of SK&F 83822 [3-allyl-6-chloro-7,8-dihydroxy-1-(3-methylphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine], an agonist at dopamine D1-like receptors which stimulate adenylyl cyclase but not phosphoinositide hydrolysis, were studied topographically so as to clarify differences between these receptors in the regulation of behaviour. Using cloned receptors, SK&F 83822 showed high, selective affinity for dopamine D1 and D5 over D2, D3, D4 and several non-dopamine receptors. SK&F 83822 induced little intense grooming, but readily induced sniffing, locomotion and rearing; seizures were evident at higher doses, characterised by tonic convulsions, forepaw myoclonus and explosive hyperlocomotion. The dopamine D1-like receptor antagonist SCH 23390 [R(+)-3-methyl-7-chloro-8-hydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine] readily antagonised these responses to SK&F 83822, particularly seizure activity. The dopamine D2-like receptor antagonist YM 09151-2 [cis-N-(1-benzyl-2-methyl-pyrrolidin-3-yl)-5-chloro-2-methoxy-4-methylaminobenzamide] did not alleviate seizures induced by SK&F 83822; YM 09151-02 did, however, attenuate SK&F 83822-induced sniffing, locomotion and rearing, and released vacuous chewing. These findings indicate that dopamine D1-like receptors linked to adenylyl cyclase can be differentiated from those not linked to adenylyl cyclase in terms of their roles in the topographical regulation of behaviour. For example, the seizure and vacuous chewing responses appear to involve dopamine D1-like receptors that stimulate adenylyl cyclase, while intense grooming involves those which do not.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14985049     DOI: 10.1016/j.ejphar.2004.01.004

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  16 in total

Review 1.  Phenotypic studies on dopamine receptor subtype and associated signal transduction mutants: insights and challenges from 10 years at the psychopharmacology-molecular biology interface.

Authors:  John L Waddington; Colm O'Tuathaigh; Gerard O'Sullivan; Katsunori Tomiyama; Noriaki Koshikawa; David T Croke
Journal:  Psychopharmacology (Berl)       Date:  2005-09-29       Impact factor: 4.530

2.  Rotation and immediate-early gene expression in rats treated with the atypical D1 dopamine agonist SKF 83822.

Authors:  David Wirtshafter
Journal:  Pharmacol Biochem Behav       Date:  2007-01-20       Impact factor: 3.533

3.  Effects of SKF83959 on the excitability of hippocampal CA1 pyramidal neurons: a modeling study.

Authors:  Shang-Lin Zhou; Hong-Yuan Chu; Guo-Zhang Jin; Jian-Min Cui; Xue-Chu Zhen
Journal:  Acta Pharmacol Sin       Date:  2014-05-26       Impact factor: 6.150

4.  SKF-83959 is not a highly-biased functionally selective D1 dopamine receptor ligand with activity at phospholipase C.

Authors:  Sang-Min Lee; Andrew Kant; Daniel Blake; Vishakantha Murthy; Kevin Boyd; Steven J Wyrick; Richard B Mailman
Journal:  Neuropharmacology       Date:  2014-06-12       Impact factor: 5.250

5.  Dopamine in the dorsal hippocampus impairs the late consolidation of cocaine-associated memory.

Authors:  Cecilia P Kramar; Vladimir I Chefer; Roy A Wise; Jorge H Medina; M Flavia Barbano
Journal:  Neuropsychopharmacology       Date:  2014-01-20       Impact factor: 7.853

6.  Molecular cloning and characterization of crustacean type-one dopamine receptors: D1alphaPan and D1betaPan.

Authors:  Merry C Clark; Deborah J Baro
Journal:  Comp Biochem Physiol B Biochem Mol Biol       Date:  2006-01-19       Impact factor: 2.231

7.  Arthropod D2 receptors positively couple with cAMP through the Gi/o protein family.

Authors:  Merry C Clark; Deborah J Baro
Journal:  Comp Biochem Physiol B Biochem Mol Biol       Date:  2006-10-10       Impact factor: 2.231

8.  D1-D2 dopamine receptor synergy promotes calcium signaling via multiple mechanisms.

Authors:  Lani S Chun; R Benjamin Free; Trevor B Doyle; Xi-Ping Huang; Michele L Rankin; David R Sibley
Journal:  Mol Pharmacol       Date:  2013-05-16       Impact factor: 4.436

Review 9.  Dopamine D1 receptor signaling: does GαQ-phospholipase C actually play a role?

Authors:  Sang-Min Lee; Yang Yang; Richard B Mailman
Journal:  J Pharmacol Exp Ther       Date:  2014-07-22       Impact factor: 4.030

10.  Dopamine D1 vs D5 receptor-dependent induction of seizures in relation to DARPP-32, ERK1/2 and GluR1-AMPA signalling.

Authors:  Gerard J O'Sullivan; Mark Dunleavy; Kerstin Hakansson; Mario Clementi; Anthony Kinsella; David T Croke; John Drago; Allen A Fienberg; Paul Greengard; David R Sibley; Gilberto Fisone; David C Henshall; John L Waddington
Journal:  Neuropharmacology       Date:  2008-02-21       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.